Literature DB >> 12764050

Parkin mutations are frequent in patients with isolated early-onset parkinsonism.

Magali Periquet1, Morwena Latouche, Ebba Lohmann, Nina Rawal, Giuseppe De Michele, Sylvain Ricard, Hélio Teive, Valérie Fraix, Marie Vidailhet, David Nicholl, Paolo Barone, Nick W Wood, Salmo Raskin, Jean-François Deleuze, Yves Agid, Alexandra Dürr, Alexis Brice.   

Abstract

Parkin gene mutations are reported to be a major cause of early-onset parkinsonism (age at onset < or = 45 years) in families with autosomal recessive inheritance and in isolated juvenile-onset parkinsonism (age at onset <20 years). However, the precise frequency of parkin mutations in isolated cases is not known. In order to evaluate the frequency of parkin mutations in patients with isolated early-onset parkinsonism according to their age at onset, we studied 146 patients of various geographical origin with an age at onset < or = 45 years. All were screened for mutations in the parkin gene using semi-quantitative polymerase chain reaction combined with sequencing of the entire coding region. We identified parkin mutations in 20 patients including three new exon rearrangements and two new missense mutations. These results, taken in conjunction with those of our previous study (Lücking et al., 2000) show that parkin mutations account for at least 15% (38 out of 246) of our early-onset cases without family history, but that the proportion decreases significantly with increasing age at onset. There were no clinical group differences between parkin cases and other patients with early-onset parkinsonism. However, a single case presenting with cerebellar ataxia several years before typical parkinsonism extends the spectrum of parkin related-disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12764050     DOI: 10.1093/brain/awg136

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  73 in total

Review 1.  Early diagnosis and therapy of Parkinson's disease: can disease progression be curbed?

Authors:  Sagar Kansara; Akash Trivedi; Sheng Chen; Joseph Jankovic; Weidong Le
Journal:  J Neural Transm (Vienna)       Date:  2012-06-26       Impact factor: 3.575

2.  Parkin mono-ubiquitinates Bcl-2 and regulates autophagy.

Authors:  Dong Chen; Feng Gao; Bin Li; Hongfeng Wang; Yuxia Xu; Cuiqing Zhu; Guanghui Wang
Journal:  J Biol Chem       Date:  2010-10-02       Impact factor: 5.157

Review 3.  Gene-environment interactions in Parkinson's disease: specific evidence in humans and mammalian models.

Authors:  Jason R Cannon; J Timothy Greenamyre
Journal:  Neurobiol Dis       Date:  2012-07-07       Impact factor: 5.996

Review 4.  New developments in diagnosis and treatment of Parkinson's disease--from basic science to clinical applications.

Authors:  Alexander Storch; Anne Hofer; Rejko Krüger; Jörg B Schulz; Jürgen Winkler; Manfred Gerlach
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

5.  Early-onset Parkinson's disease caused by a novel parkin mutation in a genetic isolate from north-eastern Brazil.

Authors:  Hsin F Chien; Christan F Rohé; Maria D L Costa; Guido J Breedveld; Ben A Oostra; Egberto R Barbosa; Vincenzo Bonifati
Journal:  Neurogenetics       Date:  2005-11-22       Impact factor: 2.660

6.  Neuropsychological Profile of Parkin Mutation Carriers with and without Parkinson Disease: The CORE-PD Study.

Authors:  Elise Caccappolo; Roy N Alcalay; Helen Mejia-Santana; Ming-X Tang; Brian Rakitin; Llency Rosado; Elan D Louis; Cynthia L Comella; Amy Colcher; Danna Jennings; Martha A Nance; Susan Bressman; William K Scott; Caroline M Tanner; Susan F Mickel; Howard F Andrews; Cheryl Waters; Stanley Fahn; Lucien J Cote; Steven Frucht; Blair Ford; Michael Rezak; Kevin Novak; Joseph H Friedman; Ronald F Pfeiffer; Laura Marsh; Brad Hiner; Andrew D Siderowf; Barbara M Ross; Miguel Verbitsky; Sergey Kisselev; Ruth Ottman; Lorraine N Clark; Karen S Marder
Journal:  J Int Neuropsychol Soc       Date:  2010-11-24       Impact factor: 2.892

7.  Analysis of exon dosage using MLPA in South African Parkinson's disease patients.

Authors:  Rowena J Keyser; Debbie Lombard; Rene Veikondis; Jonathan Carr; Soraya Bardien
Journal:  Neurogenetics       Date:  2009-12-15       Impact factor: 2.660

8.  Parkin-knockout mice did not display increased vulnerability to intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

Authors:  Aderbal S Aguiar; Fabrine S M Tristão; Majid Amar; Caroline Chevarin; Laurence Lanfumey; Raymond Mongeau; Olga Corti; Rui D Prediger; Rita Raisman-Vozari
Journal:  Neurotox Res       Date:  2013-04-16       Impact factor: 3.911

9.  E3 ubiquitin ligase PARK2, an inhibitor of melanoma cell growth, is repressed by the oncogenic ERK1/2-ELK1 transcriptional axis.

Authors:  Valentina Montagnani; Luisa Maresca; Alessandro Apollo; Sara Pepe; Ryan M Carr; Martin E Fernandez-Zapico; Barbara Stecca
Journal:  J Biol Chem       Date:  2020-09-16       Impact factor: 5.157

10.  Identification and characterization of a novel endogenous murine parkin mutation.

Authors:  Chenere P Ramsey; Benoit I Giasson
Journal:  J Neurochem       Date:  2010-01-20       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.